Deuruxolitinib phosphateProduct ingredient for Deuruxolitinib
- Name
- Deuruxolitinib phosphate
- Drug Entry
- Deuruxolitinib
Deuruxolitinib is a deuterated form of ruxolitinib that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the duration of the pharmacological activity of deuruxolitinib.2
On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.6 Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body.1 The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory mediators.1,2,4 Deuruxolitinib works to block the inflammatory responses caused by JAKs.5
- Accession Number
- DBSALT003523
- Structure
Structure for Deuruxolitinib phosphate (DBSALT003523)
- Synonyms
- (3R)-3-(2,2,3,3,4,4,5,5-D8)CYCLOPENTYL-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)PROPANENITRILE PHOSPHATE (1:1) / 1H-PYRAZOLE-1-PROPANENITRILE, .BETA.-(CYCLOPENTYL-2,2,3,3,4,4,5,5-D8)-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (.BETA.R)-, PHOSPHATE / C-21543 PHOSPHATE / CTP-543 PHOSPHATE / D8-RUXOLITINIB PHOSPHATE